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Cell Host & Microbe
CorrespondenceLack of Duffy Antigen Receptor for
Chemokines: No Influence on HIV
Disease Progression in an African
Treatment-Naive PopulationHe et al. recently reported an association
between a single-nucleotide polymor-
phism (SNP) (rs2814778, 46T/C) in the
erythroid-specific promoter region of the
Duffy antigen receptor for chemokine
(DARC) and HIV-1 acquisition and disease
progression inAfricanAmericans (He et al.,
2008). The authors described a higher
frequency of the null homozygous geno-
type (46C/C) in HIV-infected (70%)
versus noninfected individuals (60%).
Based on these findings, they argued that
thenull alleleconfers susceptibility to infec-
tion with HIV-1 and suggested that up to
11% of the HIV-1 burden in sub-Saharan
Africa could be attributed to homozygosity
for the null allele. Oddly, however, these
authors reported that the null genotype
associated with better outcomes among
those who became infected, including
longer survival and, more particularly,
decelerated loss of CD4+ T lymphocytes.
Another report showed an association
between the46C/C genotype and signif-
icantly reduced total white blood cells
(WBCs) in African Americans, explaining20% of population variation in WBCs
(Nalls et al., 2008). The 46C/C genotype
isnearly fixed in those sub-SaharanAfrican
populations where Plasmodium vivax is
endemic, apparently because it confers
resistance against P. vivax malaria, but
46C is virtually absent in individuals of
European descent (Tournamille et al.,
1995; Hamblin and Di Rienzo, 2000). In
those regions of sub-Saharan Africa that
are not endemic for P. vivax, the 46C
allele is not fixed, however; and the wild-
type (46T) allele is frequently observed
(Rosenberg, 2007). Considering the poten-
tial importance of DARC on HIV-1 disease
progression in Africans, we studied the
effect of the DARC 46 genotype on
outcomes to HIV infection in a cohort of
untreatedblackSouthAfricans. This region
of Africa is not endemic forP. vivax and lies
outsideof theareaof96%meanfixation for
46C; thus, the null allele of DARC is not
fixed in our study population, and the allele
frequency of 46T (the wild-type allele) is
about 20%. We assessed the effects of
the null (C/C), heterozygous (T/C), andCell Host & Microwild-type (T/T) genotypes on rates of CD4
decline and mean HIV-1 viral loads in
a group of 381 untreated black South
Africans. Since the 46C/C genotype has
previously been associated significantly
with reduced total WBCs (Nalls et al.,
2008), we also determined WBCs in our
cohort in order to verify that our cohort is
sufficiently powered to detect an effect
of the 46 genotype, where 46C/C is
expected to associate with low WBCs as
previously demonstrated.
HIV-1-positive seroprevalent and anti-
retroviral therapy naive subjects (n =
381) were recruited at McCord Hospital
in Durban, South Africa from August
2003 to June 2006 and have been fol-
lowed up to the present time. All subjects
belonged to the local black Zulu/Xhosa
population. Informed consent was ob-
tained from all participating individuals,
and the study was approved by institu-
tional review boards at the University of
KwaZulu Natal, Massachusetts General
Hospital, and the University of Oxford.
Viral load was measured using the Roche
AMPLICOR version 1.5 assay. The mean
viral load of the entire cohort was 4.59
(log10) HIV RNA copies per ml plasma
(interquartile range [IQR], 1.69 [log10]–
6.81 [log10]). CD4
+ T cell, CD8+ T cell, total
lymphocyte, and total white cell counts
were determined by flow cytometry. The
median CD4+ T cell count of all individ-
uals was 350 cells per ml (IQR, 7–1161).be 5, May 21, 2009 ª2009 Elsevier Inc. 413
Cell Host & Microbe
CorrespondenceTable 1. No Effect of the 46 DARC Polymorphism on HIV Disease Outcomes
Genotype N Mean sqrtCD4 P (t test)
T/T 15 18.25 T/T versus T/C 0.99
T/C 119 18.36 T/C versus C/C 0.26
C/C 247 17.61 C/C versus T/T 0.69
Genotype N Mean logVL P (t test)
T/T 15 4.58 T/T versus T/C 0.79
T/C 118 4.51 T/C versus C/C 0.20
C/C 243 4.63 C/C versus T/T 0.82
Genotype N SqrtCD4 change over time P (F test)
T/T 15 0.09 T/T versus T/C 0.14
T/C 119 0.21 T/C versus C/C 0.35
C/C 247 0.27 C/C versus T/T 0.30
Genotype N Mean total WBC (3109/l) P (t test)
T/T 15 5.84 T/T versus T/C 0.95
T/C 117 5.79 T/C versus C/C 1 3 108
C/C 244 4.75 C/C versus T/T 0.014The DARC 46T/C (rs2814778) SNP
was genotyped by TaqMan allelic
discrimination assays in all subjects,
and the genotypes were verified by direct
sequence analysis of 78 samples, where
complete concordance of genotypes
between the two assays was observed.
Association with rate of CD4 decline
was tested using a mixed linear model
for longitudinal data assuming random
effects. Pairwise comparisons between
genotype groups for CD4+ T cell counts
and viral load were done with a t test,
using the square root of the CD4+ T cell
counts and the log of the viral load to
give these data approximate normal
distributions.
In total, 247 (64.8%) patients were
homozygous for the null allele (C/C),
119 were heterozygous (T/C, 31.2%),
and 15 patients were homozygous wild-
type (T/T, 3.9%) (Table 1). The distribution
of genotypes in our cohort was consistent
with the Hardy-Weinberg equilibrium
(expected numbers: T/T, 14.6; T/C, 119.9;
C/C, 246.6; chi-square value = 0.0198,
p value = 0.888), allowing us to conduct
the following comparisons. Furthermore,
we performed a power calculation to
confirm that we were able to detect signif-
icant differences for square root CD4 and
log VL values comparing the C/C and T/C
genotype; our sample size has 80%power
to detect differences of 12% and 7%,
respectively, for the two measures. No
significant difference was observed with
respect to median CD4 counts and VL414 Cell Host & Microbe 5, May 21, 2009 ªamong the C/C (sqrtCD4, 17.61; log10VL,
4.63), T/C (sqrtCD4, 18.36; log10VL, 4.51),
and T/T (sqrtCD4, 18.25; log10VL, 4.58)
subgroups. To investigate the influence
of the DARC genotype on disease
progression, we compared rates of CD4+
T cell decline among the three groups.
Individuals with the 46C/C genotype
showed a CD4 decline of 0.27 sqrtCD4,
as compared to 0.21 and 0.09
from patients with 46T/C or 46T/T,
respectively. These differences were not
statistically different, indicating that
the DARC genotype does not have an
effect on the rate of CD4 decline in our
cohort.
There was also no impact of the DARC
SNP on total CD8+ T cell count or total
lymphocyte counts (data not shown).
However, consistent with a recent report
(Nalls et al., 2008), individuals expressing
the 46C/C genotype exhibited signifi-
cantly lower levels of total WBCs (4.75 3
109/l) compared to patients with the
46T/C (5.79 3 109/l) or 46T/T (5.84 3
109/l) genotypes (p = 1 3 108 and p =
0.014, respectively). Limitations to our
study include sample size and potential
confounding effects by other unknown
polymorphisms. However, our data con-
vincingly replicate an effect of the 46
locus on total white cell count, indicating
that our cohort is powered to detect
true effects of this locus, but do not
support any effect of the 46 variant on
outcomes to HIV infection that were
tested here.2009 Elsevier Inc.The profound implications of the He
et al. report (He et al., 2008) suggesting
an effect of the 46 DARC polymorphism
on susceptibility to HIV-1 infection and
HIV disease progression in African Amer-
icans warrant further, careful examina-
tion, especially as stratification due to
population substructure can create
spurious associations between alleles
and traits that differ across subpopula-
tions. This applies in particular to African
Americans where the DARC null allele
may have a particularly large stratification
effect. Among the 381 untreated black
South Africans studied here, there are no
differences in total mean CD4 counts,
decline in CD4 counts over time, or
mean HIV viral load among the different
DARC genotypes. These data indicate
that the 46C/C DARC SNP does not
play a major role in HIV disease progres-
sion in this cohort of Zulu/Xhosa HIV clade
C-infected South Africans. However, the
impact of the SNP on reduced WBC
counts was clearly replicated in this pop-
ulation, an effect that has now been
shown to be attributable to differences in
neutrophil numbers rather than to differ-
ences in lymphocyte populations (Reich
et al., 2009). We conclude that if the
DARC 46 polymorphism has an effect
on survival among HIV-1-infected people
of African descent as previously reported
(He et al., 2008), this effect is independent
of CD4+ T cell loss and plasma viral load
burden.
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He et al. recently reported the absence
of erythrocyte Duffy antigen/receptor for
chemokines (DARC) expression leads to
increased risk of acquiring HIV but slower
rates of disease progression (He et al.,
2008). We had also hypothesized DARC
may have a role in HIV pathogenesis and
progression by either influencing the
number of binding sites available to the
virus and its consequent distribution or by
acting as reservoir for chemokines, altering
the pattern of their release and thereby
decreasing in magnitude but prolonging in
duration the immune activation by which
DARC may influence HIV outcomes. To
investigate this, we identified the Duffy
genotype in African-American men from
the Multicenter AIDS Cohort Study
(MACS) and compared the time to AIDS
and death.
Sexually active homosexual or bisexual
men, without known AIDS, were recruited
as previously described (Kaslow et al.,
1987). From 5622 men enrolled before
2001, 295 HIV-infected African American
participantsweregenotyped.Thesequence
for the DARC polymorphisms of interest as
described by Tournamille et al. and the
primers were based on that reference
sequence (Tournamille et al., 1995).
Primary outcomes for analysis were
time from HIV-1 seroconversion to AIDS
and time to death. If seroconversion
occurred prior to recruitment in the study,
date of study entry was used as serocon-
version date, while, for those who sero-
converted during follow-up period, the
midpoint between the dates of last HIV-Nalls, M.A., Wilson, J.G., Patterson, N.J., Tandon,
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negative visit and first HIV-positive visit
was used.
Exposure was defined first on the basis
of erythrocyte promoter: those with the
null mutation in the erythrocyte promoter
are referred to as mutation type, where
those expressing Fy, regardless of open
reading frame (ORF) allele, are wild-type
(wt). Participants can therefore be grouped
as those who are homozygous for the null
mutation (mt/mt), those who are heterozy-
gous for the null mutation (mt/wt), or those
who are homozygous for the wild-type
(wt/wt). This analysis will reflect receptor
numbers on red blood cells, which is
proportional toagenedosageeffect (Wool-
ley et al., 2000). Second, groups or virtual
phenotypes are defined on the basis of
DARC expression, combining their ORF
allele (Fya or Fyb) with their erythrocyte
promoter mutation. This analysis reflects
the type of receptor on red blood cells.
The primary exposures in the analysis
are the promoter genotype, for which wt/
wt is the reference group. Covariates
controlled for in multivariate analysis
included calendar periods (before 1990
[reference group], 1990—1994, 1995—
1999, and post-2000), age at HIV-1 infec-
tion, and highly active antiretroviral therapy
(HAART) treatment experience prior to
events. Calendar period and HAART use
were treated as time-dependent covari-
ates. Cox proportional hazard regression
analysis models with time-dependent co-
variates were used to calculate the relative
hazard for predictors by using SAS 9.1
(SAS Institute). The assumptions of the
Cell Host & MicroW.C., Cheng, C.Y., Coresh, J., et al. (2009). PLoS
Genet. 5, e1000360.
Rosenberg, R. (2007). Trends Parasitol. 23, 193–
196.
Tournamille, C., Colin, Y., Cartron, J.P., and Le Van
Kim, C. (1995). Nat. Genet. 10, 224–228.proportional hazards model were deemed
accurate based on the insignificant coeffi-
cient of the interaction term evaluating key
predictors and time that was obtained.
Kaplan-Meier curves were generated by
S-plus 8.1 (Insightful Corporation). An iden-
tical analysis was performed using
promoter and open reading frame haplo-
types, which reflect DARC phenotypes
(Fy is the reference group) as the primary
exposure.
In addition, the binomial test of propor-
tions was used to compare the frequency
distribution for DARC phenotype between
HIV antibody-positive men in this study to
a previously tested group of African-
American blood donors.
Of the 295 African-American men
included in this study, 249 were HIV posi-
tive at the time of recruitment to the study
(seroprevalent), and the remaining 46 se-
roconverted during follow-up. For the se-
roprevalent, theaverageageat studyentry
was32.5yearsoldandmedianCD4+Tcell
counts 505 cells/mm3. For seroconvert-
ers, average age at seroconversion was
32.1 years and median CD4+ T cells was
588 cells/mm3 at the first HIV positive visit.
One hundred and seventy-four of the
participants (59.0%) were homozygous
for the erythrocyte promoter null mutation,
ninety-eight (33.2%) heterozygous, and
twenty-three (7.8%) had wt expression.
Predicted values were 169, 109, and 18
respectively (rounded to the nearest
integer). This distribution conforms to the
Hardy-Weinberg equation (p = 0.087
when tested for violation).
Overall, 104 developed AIDS (26 diag-
nosed before 1990, 52 diagnosed 1990–
1994, 23 diagnosed 1995–1999, and 3
diagnosed after 2000) and 141 died (19
died before 1990, 62 died 1990–1994,
50 died 1995–1999, and 10 died after
2000) as of March 31, 2007. Univariately,
time to AIDS or time to death did not differ
for the mt/mt and mt/wt groups compared
be 5, May 21, 2009 ª2009 Elsevier Inc. 415
